FOR IMMEDIATE RELEASE

May 3, 2023

Media Contact:

Cole Archer

Director of Marketing & Communications

Communication@LissMD.com

(706) 327-4000

 

Eli Lilly and Company (NYSE: LLY) have announced that Alzheimer’s drug, donanemab, showed the ability to significantly slow cognitive decline in those with early symptomatic Alzheimer’s disease. Eli Lilly stated that they plan to file for FDA approval on this drug by the end of June.  Columbus, Georgia, home to Columbus Memory Center, once again played a substantial role in this drug’s journey to success.

COLUMBUS, GA. May 3rd, 2023 – Columbus Memory Center is proud to share exciting news in the fight against Alzheimer’s Disease. Trailblazer-ALZ 2, the clinical trial of the investigational drug, donanemab, has produced positive results during its Phase 3 trial period. The treatment reduced clinical decline on the global cognitive and functional scale, CDR-SB, by 35% compared to placebo.

“…We believe our data meets the ‘high level of evidence’ the Centers for Medicare & Medicaid Services (CMS) has described as the trigger for reconsideration of its National Coverage Determination. People with early Alzheimer’s disease need and deserve full coverage and access for approved therapies,” Anne White, executive vice president, Eli Lilly, and president of Lilly Neuroscience, said in a statement.

“These drugs actually take the protein out of the brain that we believe starts the disease,” said Neurologist Dr. Liss, President of Columbus Memory Center and Site Principal Investigator.  “In fact, we’re using one of these drugs as prevention in a research trial to see if we can stop Alzheimer’s disease from ever starting. This, of course, gives us even more confidence that it may work!”

About Columbus Memory Center

Columbus Memory Center is a world leader in Alzheimer’s clinical care and research. The center is credited for its commitment to ending Alzheimer’s in this generation through initiatives such as the Columbus Memory Project and the creation of the world’s first vital sign for brain health, the Memory Number®.  For more information about Columbus Memory Center, visit www.columbusmemorycenter.com.

More information about donanemab or Eli Lilly and Company can be found in their press release available here.